Organovo Holdings, Inc. (NASDAQ:ONVO) Stock Holdings Lowered by ARK Investment Management LLC

ARK Investment Management LLC lowered its position in shares of Organovo Holdings, Inc. (NASDAQ:ONVOGet Rating) by 4.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 291,633 shares of the medical research company’s stock after selling 14,475 shares during the quarter. ARK Investment Management LLC’s holdings in Organovo were worth $703,000 as of its most recent SEC filing.

Wall Street Analyst Weigh In

Separately, started coverage on shares of Organovo in a report on Sunday. They set a “sell” rating on the stock.

Organovo Price Performance

ONVO stock opened at $2.23 on Tuesday. Organovo Holdings, Inc. has a 52-week low of $1.71 and a 52-week high of $7.41. The company’s 50 day simple moving average is $2.79 and its 200-day simple moving average is $2.82. The firm has a market capitalization of $19.43 million, a P/E ratio of -1.60 and a beta of 1.14.

Organovo (NASDAQ:ONVOGet Rating) last released its quarterly earnings results on Thursday, August 11th. The medical research company reported ($0.37) earnings per share (EPS) for the quarter.

Organovo Company Profile

(Get Rating)

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.

See Also

Want to see what other hedge funds are holding ONVO? Visit to get the latest 13F filings and insider trades for Organovo Holdings, Inc. (NASDAQ:ONVOGet Rating).

Institutional Ownership by Quarter for Organovo (NASDAQ:ONVO)

Receive News & Ratings for Organovo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo and related companies with's FREE daily email newsletter.